Mikael Engblom

Mikael Engblom discloses dealings in Vitrolife AB to Finansinspektionen. The record holds 39 filings, for trades running from 22 July 2016 to 6 September 2021.

In open-market terms, that means 12 purchases worth €70k on one side and 27 sales worth €683k on the other. Taken together, the sales exceed the purchases by €613k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2021, the count stands at 1 purchase and 19 sales.

Half of the purchases are above €6,878 and half below. On 2 out of 11 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 6 September 2021: an open-market sale of €27k, in Vitrolife AB. The last purchase on record was published on 15 July 2021, which is 1,942 days ago. The median gap between trade and publication is zero days: most filings appear on the same day. Under the Market Abuse Regulation, managers have three business days to notify their trades. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.